Latest news with #pennyStocks
Yahoo
a day ago
- Business
- Yahoo
DeFi Technologies (DEFT) Expands into Middle East with Dubai Trading Hub
DeFi Technologies Inc. (NASDAQ:DEFT) is one of the best high-return penny stocks to buy now. On July 14, the company announced the opening of a branch in Dubai to meet the growing demand for digital assets in the region. The opening is part of the company's effort to capitalize on growth opportunities in the Middle Eastern markets. A businessman in a suit, counting stacks of money in front of a graph of a mortgage finance market. Consequently, the company has opened a dedicated trading desk within the Dubai Multi Commodities Center (DMCC) in the United Arab Emirates (UAE). The trading desks will allow DeFi Technologies to capitalize on surging institutional interest in digital assets across the Middle East. 'We believe the demand for digital asset ETPs will increase not only globally but in the GCC and Middle East. Investors, whether sovereign wealth funds, institutional investors, family offices, and even retail investors, are interested in crypto but require familiar and efficient vehicles to get exposure,' Fortson stated. Similarly, DeFi Technologies has broadened its reach with the opening of operations in Turkey through collaboration with Misyon Bank and Misyon Kripto. DeFi Technologies Inc. (NASDAQ:DEFT) is a financial services company focused on bridging the gap between traditional capital markets and decentralized finance (DeFi). It achieves this by offering regulated and secure access to digital assets and DeFi applications through various ventures, including Valour, Stillman Digital, Reflexivity Research, and Neuronomics. While we acknowledge the potential of DEFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
a day ago
- Business
- Yahoo
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition
Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now. On July 1, Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and an $8.00 price target, citing strong prospects following its acquisition of EXXUA. Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition A scientist in a lab running tests on a variety of biopharmaceuticals. The antidepressant's unique mechanism reportedly avoids two major side effects common in the category, giving it a competitive edge in a saturated yet underserved market. Lake Street expects EXXUA's rollout to significantly boost Aytu's revenue profile by FY 2027, and believes further stock gains are likely as generic concerns ease and product adoption grows. Aytu BioPharma, Inc. (NASDAQ:AYTU) is a pharmaceutical company that develops and commercializes innovative therapies in the U.S. and globally. Its product lineup includes ADHD treatments like Adzenys XR-ODT and Cotempla XR-ODT, as well as pediatric medications such as Karbinal ER for allergies and fluoride-based multivitamins Poly-Vi-Flor and Tri-Vi-Flor for infants and children. While we acknowledge the potential of AYTU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
a day ago
- Business
- Yahoo
Taseko Mines (TGB) Price Target Hiked on positive Section 232 Tariffs Impact Prospects
Taseko Mines Ltd. (NYSE:TGB) is one of the best high-return penny stocks to buy now. On July 16, analysts at TD Securities increased their price target for the stock to C$5 from C$3.50 but downgraded the rating to 'Hold' from 'Buy'. Taseko Mines (TGB) Price Target Hiked on positive Section 232 Tariffs Impact Prospects A large open-pit copper mine with heavy machinery extracting minerals from the earth. The adjustment came amid valuation concerns, as the stock was trading at 1.3 times net asset value and 5.7 times estimated 2026 EBITDA. According to the analyst Craig Hutchison, the stock is fully valued, even as they expect the stock price to increase. In addition, analysts expect Taseko mine valuations to receive a significant boost if Section 232 tariffs take effect, given the potential positive impact on the Taseko Florence project. Taseko Mines Ltd. (NYSE:TGB) is a North American mining company focused on the operation and development of copper mines. It owns and operates the Gibraltar Mine, a large copper and molybdenum mine located in British Columbia. It's also developing the Florence Copper project in Arizona, which uses a unique in-situ recovery method. While we acknowledge the potential of TGB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16-07-2025
- Business
- Yahoo
UBS Affirms ‘Buy' Rating on Evgo (EVGO) Amid Profitability Prospects
Evgo, Inc. (NASDAQ:EVGO) is one of the best green energy penny stocks to buy right now. On June 17, UBS reiterated a 'Buy' rating and a $5 price target. UBS views the company as its preferred electric vehicle charging investment as it is poised to benefit from various catalysts. A row of charging stations glowing with the power of the sun ready for public use. For starters, the research firm has echoed the long-term impact of additional Department of Energy loan disbursements. It expects the disbursements to provide Evgo with extra capital. In addition, UBS expects the company to achieve its first-ever positive adjusted EBITDA quarter in Q2, marking an essential step toward profitability. Consequently, UBS expects Evgo to generate adjusted EBITDA of $3.5 million in 2025, $36.4 million in 2026, and $61.8 million in 2027. In the first quarter, the company generated $75.3 million in revenues, better than the $71.4 million that analysts expected. Evgo, Inc. (NASDAQ:EVGO) is a leading provider of fast charging stations for electric cars, making it easier for people to own and use EVs. It builds and operates a public fast-charging network for electric vehicles. While we acknowledge the potential of EVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Popular AI Penny Stocks to Buy According to Billionaires and 10 Best Defensive Stocks to Buy in a Volatile Market. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
ASX Penny Stocks Spotlight: Clarity Pharmaceuticals And 2 More Standouts
The Australian market is poised for a rebound, with shares expected to rise following Wall Street's positive momentum, largely driven by Nvidia's remarkable performance. In the context of this optimistic market backdrop, penny stocks—often smaller or newer companies—continue to intrigue investors despite being considered an outdated term. These stocks can offer unique growth opportunities and financial resilience that may not be as prevalent in larger firms. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.35 A$100.31M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.23 A$105.2M ★★★★★★ GTN (ASX:GTN) A$0.625 A$119.2M ★★★★★★ IVE Group (ASX:IGL) A$2.92 A$450.21M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.735 A$458.75M ★★★★★★ Regal Partners (ASX:RPL) A$2.44 A$820.39M ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$360M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.71 A$838.04M ★★★★★☆ Bisalloy Steel Group (ASX:BIS) A$4.02 A$190.75M ★★★★★★ CTI Logistics (ASX:CLX) A$1.795 A$144.58M ★★★★☆☆ Click here to see the full list of 465 stocks from our ASX Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company focused on the research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$895.84 million. Operations: The company's revenue is derived from its radiopharmaceutical development segment, totaling A$10.78 million. Market Cap: A$895.84M Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a market cap of A$895.84 million, is pre-revenue and currently unprofitable. Despite this, the company has made significant strides in its development pipeline. Recent agreements like the Commercial Manufacturing Agreement with SpectronRx enhance its manufacturing capabilities for 64Cu-SAR-bisPSMA in the US, potentially positioning it well for commercial rollout pending successful trials and FDA approval. Clarity's robust cash position exceeds both short- and long-term liabilities, providing a runway to continue advancing clinical trials such as AMPLIFY and DISCO without incurring debt. Unlock comprehensive insights into our analysis of Clarity Pharmaceuticals stock in this financial health report. Assess Clarity Pharmaceuticals' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: IGO Limited is an exploration and mining company in Australia that focuses on discovering, developing, and operating assets related to metals for clean energy, with a market cap of A$3.32 billion. Operations: The company's revenue is primarily derived from its Nova Operation, which generated A$460.8 million, and its Forrestania Operation, contributing A$153 million. Market Cap: A$3.32B IGO Limited, with a market cap of A$3.32 billion, operates primarily through its Nova and Forrestania operations, generating significant revenues of A$460.8 million and A$153 million respectively. Despite being unprofitable and having a negative return on equity, IGO's financial health is bolstered by its debt-free status and strong asset position, with short-term assets significantly exceeding both short- and long-term liabilities. The company is trading well below estimated fair value but faces challenges with an inexperienced management team averaging one year in tenure. Recent executive changes aim to bolster sustainability efforts within the company. Dive into the specifics of IGO here with our thorough balance sheet health report. Evaluate IGO's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Stanmore Resources Limited is involved in the exploration, development, production, and sale of metallurgical coal in Australia with a market cap of A$1.85 billion. Operations: The company generates revenue of $2.40 billion from its metals and mining segment, specifically through coal. Market Cap: A$1.85B Stanmore Resources, with a market cap of A$1.85 billion, generates substantial revenue of $2.40 billion from its metallurgical coal operations. Despite facing challenges such as a decline in profit margins from 16.8% to 8% and negative earnings growth over the past year, the company benefits from well-covered debt by operating cash flow and satisfactory net debt to equity ratio (1%). Recent events include being dropped from key indices like the S&P/ASX 200, which might impact investor sentiment. The management team is experienced, although earnings are forecasted to decline significantly over the next three years. Get an in-depth perspective on Stanmore Resources' performance by reading our balance sheet health report here. Learn about Stanmore Resources' future growth trajectory here. Access the full spectrum of 465 ASX Penny Stocks by clicking on this link. Contemplating Other Strategies? Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:CU6 ASX:IGO and ASX:SMR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
